Europe — EMA

Onglyza (Saxagliptin)

Saxagliptin, the active ingredient in Onglyza, is a DPP‑4 inhibitor presented as a tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus.

Saxagliptin

Request sourcing

Pack/s

What is Saxagliptin?

Saxagliptin, the active ingredient in Onglyza, is a DPP‑4 inhibitor presented as a tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus. GNH USA supplies Onglyza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Onglyza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

What is Saxagliptin used for?

Onglyza is a DPP‑4 inhibitor that targets the incretin pathway to help manage blood glucose levels in type 2 diabetes. It may be used in the following clinical situations: - Type 2 Diabetes Mellitus: Improves glycaemic control as an adjunct to diet and exercise. - Combination Therapy: Enhances glucose control when added to metformin, sulfonylureas, or insulin. - Early Intervention: May be considered early in the treatment algorithm for patients inadequately controlled on lifestyle measures alone.

What are the side effects of Saxagliptin?

Side effects reported with saxophone ...

What precautions apply to Saxagliptin?

Precautions: ...

What does Saxagliptin interact with?

Major ...

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →